Clofibrate in type IIa hyperlipoproteinemia. Reduction of apolipoprotein B
Mertz, D.P.; Suermann, I.; Göhmann, E.
Münchener Medizinische Wochenschrift 120(34): 1097-1099
1978
ISSN/ISBN: 0341-3098 PMID: 210375 Document Number: 137515
After changing over from the usual eating habits to a "reasonable" restricted diet rich in polyene saturated fats and saturated fatty acids, additional treatment with 1 g clofibrate twice daily produces a significant reduction of concentration of total cholesterol and Apo B by about 24% in the serum of patients with Type IIa hyperlipoproteinemia after 2 weeks. In contrast to this the serum concentration of triglycerides and phospholipids shows an insignificant tendency to fall during the whole duration of the trial. The results suggest that the additional cholesterol reducing action of clofibrate in patients with hyperlipoproteinemia Type IIa who have already been treated by diet is mainly achieved by the reduction of LDL-cholesterol, the atherogenic properties of which are well known.